5-HT1B Receptor Modulators With Reduced Brain Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel, more selective and safe 5-HT1B receptor modulators with improved polarity and less brain penetration to treat peripheral diseases such as cancer, respiratory diseases, and hepatic disorders, while minimizing side effects on the central nervous system.
Innovation Solution
Development of new compounds of formula (I) with specific structural features, including various substituents and pharmaceutically acceptable salts, designed to selectively modulate the 5-HT1B receptor with reduced brain penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing 5-HT1B receptor modulators are used to treat peripheral diseases, then therapeutic effect is achieved, but CNS side effects occur due to brain penetration
Solution Approach 1:
The patent applies local quality by modifying specific regions of the molecule to alter its distribution properties. The introduction of polar groups at strategic positions creates localized polarity that prevents BBB penetration while preserving peripheral receptor binding, thus achieving therapeutic effect without CNS side effects
Solution Approach 2:
The patent changes the polarity parameter of the compound by introducing hydrophilic groups (such as carboxylic acid, hydroxyl, or amino groups). This parameter change reduces lipophilicity and prevents blood-brain barrier penetration, thereby eliminating CNS side effects while maintaining peripheral therapeutic activity
2Object-affected harmful factors
If compound selectivity is increased to reduce side effects, then safety profile improves, but compound development complexity increases
Solution Approach 1:
The patent segments the molecule into distinct functional regions: a core structure for 5-HT1B binding and peripheral selectivity, and polar substituents for controlling distribution. This segmentation allows independent optimization of selectivity and safety without requiring complete redesign of the entire molecule
Solution Approach 2:
The patent uses polar functional groups as intermediaries that mediate between the hydrophobic core structure and the aqueous environment. These intermediary groups reduce membrane permeability selectively at the BBB while allowing peripheral tissue access, thus improving safety without excessive complexity
Data Source
AI summary
The present invention relates to new compounds of formula (I):as modulators of serotonin receptor 1B (5-HTR1B) also known as 5-hydroxytryptamine receptor 1B (5-HT1B). The compounds are of potential utility in the treatment of diseases and conditions mediated by serotonin receptor type 1B (5-HTR1B), such as cancer, including blood cancer and solid tumors, respiratory diseases and hepatic disorders.